Egrifta sv fda approval date?

See the DrugPatentWatch profile for Egrifta

What was the FDA approval date for Egrifta SV?

Egrifta SV (tesamorelin for injection) received FDA approval on April 22, 2010. [1]

What product is Egrifta SV?

Egrifta SV is tesamorelin indicated to reduce excess abdominal fat in certain adults with HIV who have lipodystrophy. [1]

Is Egrifta SV different from older Egrifta approvals?

Yes. Egrifta (tesamorelin) and Egrifta SV are not the same labeling/product form, and FDA approval dates can differ by version. The approval date above is specifically for Egrifta SV. [1]

Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021556